Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Revenue of Day One Biopharmaceuticals, Inc. (DAWN)
Revenue in 2023 (TTM): $
According to Day One Biopharmaceuticals, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Day One Biopharmaceuticals, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-383,000 | $-206,064,000 | $-188,917,000 | $-188,917,000 |
| 2022 | $ | $-531,000 | $-141,650,000 | $-142,181,000 | $-132,176,000 |
| 2021 | $ | $-199,000 | $-72,555,000 | $-72,754,000 | $-70,442,000 |
| 2020 | $ | $-155,000 | $-43,658,000 | $-43,843,000 | $-40,506,000 |
| 2019 | $ | $ | $-2,000 | $-16,984,000 | $-14,711,000 |